| dc.contributor.author | Viljoen, M | |
| dc.date.accessioned | 2023-03-22T09:38:35Z | |
| dc.date.available | 2023-03-22T09:38:35Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Moustafa, I., Viljoen, M., Perumal-Pillay, V. A., & Oosthuizen, F. (2022). Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity. Journal of Oncology Pharmacy Practice, 107815522211476. https://doi.org/10.1177/10781552221147660 | en_US |
| dc.identifier.issn | 1078-1552, 1477-092X | |
| dc.identifier.uri | http://hdl.handle.net/10566/8631 | |
| dc.description.abstract | Objective: Doxorubicin is a valuable chemotherapeutic drug; however, it is associated with a high risk of cardiotoxicity. Several institutions and organizations have developed guidelines for risk factor assessment, monitoring, and prevention strategies against chemotherapy-induced cardiotoxicity. This review aimed to assess the quality of current practice guidelines, using the Appraisal of Guidelines for Research and Evaluation II (AGREE II). This tool was used to compare the recommendations with regards to their strength and the evidence recommendations were based on. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Journal of Oncology Pharmacy Practice | en_US |
| dc.subject | doxorubicin | en_US |
| dc.subject | assessment | en_US |
| dc.subject | monitoring | en_US |
| dc.subject | management | en_US |
| dc.subject | guideline | en_US |
| dc.title | Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity | en_US |
| dc.type | Article | en_US |
